SecBot SecBot
424B4 ·Filed Aug 27, 2026

MBAI

Check-Cap Ltd
MIXED
Impact 7/10
Horizonweeks Processed2mo ago SEC0001213900-26-094129
Prospectus supplement
Actionable Insight ◆ Mixed

This offering removes near-term financing risk and funds the pending MBody AI merger, but the ~19.6% discount and 85.6% dilution are significant negatives for existing holders. The binary catalyst is Nasdaq's initial listing approval for the combined company — monitor for that decision. If approved, the stock may re-rate on the post-merger AI robotics story; if denied, the company faces delisting and potential wind-down.

DirectionMixed
Confidencehigh
Horizonweeks
Latest settled — T+20d
MBAI ▼ -31.35% at T+20d
NEUTRAL call -31.35% · α vs SPY -30.85% · entry $6.57 → $4.51
Next anchor: T+60d in 25d
Latest observation: T+40 -52.91% FF3 residual α
Entry = T+0 close
Aug 27, 2026
via day close
T+1d
+0.15%
call +0.15% · α +0.38%
$6.58
settled 8w ago
T+5d
-1.07%
call -1.07% · α -1.33%
$6.50
settled 8w ago
T+20d
-31.35%
call -31.35% · α -30.85%
$4.51
settled 4w ago
T+60d
Pending
in 25d

Executive Summary

Check-Cap Ltd. has priced and closed a firm-commitment public offering of 1,538,462 ordinary shares at $6.50 per share, raising approximately $9.0 million in net proceeds. The offering is a critical capital raise to fund the pending transformative merger with MBody AI Corp, where former MBody AI equityholders will own ~90% of the combined company. The $6.50 offering price represents a ~19.6% discount to the $8.08 last sale price, and the new shares represent ~10.1% of the pro forma post-merger shares outstanding, causing immediate dilution of $5.56 per share (85.6%) for new investors. The company has a going-concern warning and the merger's closing is contingent on Nasdaq initial listing approval, creating binary risk.

Key Financial Metrics

Offering Size
$10.0M
Dilution
10.1%
Lock-up
180 days
Underwriters
Northland Securities, Inc.

Key Facts

  • Firm-commitment IPO of 1,538,462 ordinary shares at $6.50 per share, raising ~$9.0M net proceeds.
  • Offering price represents a ~19.6% discount to the $8.08 last closing price on August 25, 2026.
  • Proceeds earmarked for Merger fees (~$0.9M), robotic system acquisition/deployment (~$4.5M), inventory (~$0.9M), MBody AI Orchestrator development (~$1.8M), and working capital (~$0.9M).
  • New shares represent ~10.1% of pro forma post-Merger shares outstanding (15,293,552 total), causing immediate dilution of $5.56 per share (85.6%) for new investors.
  • Underwriter: Northland Securities, Inc. with a 30-day over-allotment option for up to 230,769 additional shares.
  • The offering is contingent on Nasdaq listing; the Merger (expected Q3 2026) is not contingent on this offering but on Nasdaq initial listing approval.
  • Company has a going-concern warning; Merger failure would leave ~$16.3M Apollo Loans outstanding and Apollo BCA in effect.
  • One former MBody AI shareholder will hold ~49.4% voting power post-offering and Merger (or ~48.6% with full over-allotment).
  • 180-day lock-up agreements for directors and officers.
  • Underwriting discount: $0.39 per share ($600,000.18 total).

Financial Impact

~$9.0M net proceeds raised; offering priced at a ~19.6% discount to last close; immediate dilution of $5.56 per share (85.6%) for new investors.

dilutioncashshare count

Risk Factors

  • Nasdaq may not approve the initial listing application for the combined company, leading to delisting.
  • Merger may not close by the extended December 31, 2026 outside date, leaving the company with a going-concern warning and ~$16.3M in Apollo Loans.
  • MBody AI has a limited operating history, is dependent on two customers (MGM and Caesars), and has negative operating cash flow despite reported profitability.
  • Significant dilution from this offering and the Merger (legacy Check-Cap shareholders will own ~10% of the combined company).
  • One former MBody AI shareholder will hold ~49.4% voting power, creating concentrated control risk.

Market Snapshot

Exchange
Nasdaq
Sector
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B4 Filing (Primary)0001213900-26-094129
Document: 0001213900-26-094129-index-headers.html0001213900-26-094129
Document: 0001213900-26-094129-index.html0001213900-26-094129
Document: 0001213900-26-094129.txt0001213900-26-094129
16 reports for MBAI
Performance horizon
100% Hit rate @ T+5 6 of 6 directional calls Went positive at some point 6 of 6 best @ T+20▲ +59.78%Sep 22, 2026
Filters
Rows
Reports for MBAI — sortable, filterable
TypeNow
Oct 22, 2026
4d ago
Press Release
NEUTRAL ★ 4/10
$2.05awaiting T+5—$1.95 (−4.88%)
Sep 29, 2026
27d ago
EFFECT
NEUTRAL ★ 4/10
$3.75 $3.24▼ −13.60%▼ −15.55%$1.95 (−48.00%)
Sep 22, 2026
4w ago
SC 13D
NEUTRAL ★ 4/10
$5.47 $3.54▼ −35.28%▼ −34.61%$1.95 (−64.35%)
Sep 22, 2026
4w ago
6-K
BEARISH ★ 6/10
$5.47 $3.54▲ +35.28%▲ +34.61%$1.95 (+64.35%)
Sep 16, 2026
5w ago
6-K
NEUTRAL ★ 4/10
$6.33 $5.47▼ −13.59%▼ −15.41%$1.95 (−69.19%)
Sep 16, 2026
5w ago
Press Release
NEUTRAL ★ 5/10
$6.33 $5.47▼ −13.59%▼ −15.41%$1.95 (−69.19%)
Aug 28, 2026
8w ago
Press Release
MIXED ★ 7/10
$6.61 $6.37▼ −3.71%▼ −3.56%$1.95 (−70.50%)
Aug 28, 2026
8w ago
6-K
BEARISH ★ 7/10
$6.58 $6.50▲ +1.22%▲ +1.32%$1.95 (+70.36%)
Aug 27, 2026
8w ago
424B4
MIXED ★ 7/10
$6.57 $6.50▼ −1.07%▼ −1.33%$1.95 (−70.32%)
Aug 26, 2026
8w ago
6-K
BEARISH ★ 7/10
$6.78 $6.48▲ +4.42%▲ +4.30%$1.95 (+71.24%)
Showing 10 of 16

US Market Status

Market Open — Closes in 5h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 27, 2026